41
Kyowa Kirin
4151.T·TSETokyo JPFounded 19495,700 employees
Large CappharmaPublicRare DiseaseHematologyNephrology
Platform: Crysvita FGF23
Market Cap
$10B
All Drugs
5
Clinical Trials
9
Failed / Terminated
3
FDA Approved
0
Stock Price & Catalysts (4151.T)
Loading 4151.T stock data...
Drug Pipeline (5 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| 415-3545 | 415-3545 | Phase 2/3 | 1 | PD-L1 | FTDSMA | ||
| 415-4068 | 415-4068 | NDA/BLA | 2 | DLL3 | NB | ||
| 415-3897 | 415-3897 | Phase 3 | 4 | GLP-1R | Ewing SarcomaMG | ||
| 415-7410 | 415-7410 | Phase 1 | 1 | MDM2 | PAH | ||
| Darafutibatinib | 415-3119 | NDA/BLA | 1 | GPRC5D | PompeParkinson's |
SEC Filings & Financial Documents
SEC filings are not available for TSE-listed companies.
Kyowa Kirin trades on TSE (JP). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (10)